Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (Nasdaq: ACCD) is a pioneering Personalized Healthcare company devoted to providing exceptional healthcare experiences to millions of people and their families, enabling them to live their healthiest lives. Accolade's range of solutions targets employers, health plans, and consumers by integrating virtual primary care, mental health services, expert medical opinions, and top-tier care navigation. Their innovative platform leverages cloud-based intelligent technology, coupled with expert clinical teams, including registered nurses, physician medical directors, pharmacists, and primary care physicians, to deliver comprehensive advocacy and healthcare services.
The company has been recognized for its significant contributions to the healthcare industry, such as being named one of Forbes' 25 most promising companies and achieving a spot on Inc. 500's list of America's fastest-growing private companies. Accolade's mission is to guide individuals through the complexities of the healthcare system, thereby enhancing outcomes and reducing costs for employers and health plans.
Accolade has recently gained considerable attention for its impressive 227% revenue growth, attributed to a relentless focus on delivering exceptional outcomes. This achievement earned Accolade a place in the Deloitte Technology Fast 500™ list for 2023. CEO Rajeev Singh credits the company's innovative approach and dedicated team for this remarkable performance.
Accolade's Trusted Partner Ecosystem, launched in 2019, exemplifies its commitment to comprehensive healthcare solutions. This ecosystem includes partnerships with leading companies like Kindbody and Noom, expanding access to specialized services such as fertility and metabolic health.
Accolade's financial health remains robust, with recent quarterly results showcasing a significant reduction in net loss and positive adjusted EBITDA, indicating a promising trajectory toward sustainable growth and profitability.
With a consumer satisfaction rating consistently over 90%, Accolade is steadily advancing its vision of transforming healthcare through predictive engagement, proactive care, and by addressing barriers to access and continuity of care. The company's forward-thinking approach ensures it remains at the forefront of healthcare innovation, making a significant impact on the industry and the lives of the people it serves.
For more information, visit accolade.com.
Accolade, Inc. (NASDAQ: ACCD) reported a 58% increase in fiscal Q4 2022 revenue, reaching $93.8 million compared to $59.2 million in Q4 2021. For the full fiscal year, revenue grew 82% to $310 million, up from $170.4 million. Despite strong growth, Accolade is moderating its top-line growth objectives due to a large client terminating its service relationship. The company reported a net loss of $34.6 million for Q4 and $123.1 million for the year. However, Cash reserves stand at $366 million, supporting future growth.
Accolade, Inc. (NASDAQ: ACCD) announced it will release its fiscal fourth quarter and full year 2022 financial results on April 28, 2022, after market close. A conference call will follow at 4:30 p.m. E.T. for detailed results discussion. Accolade is a healthcare provider serving over 600 employers and millions of members, focusing on personalized healthcare experiences. The company combines virtual primary care and intelligent technology to improve health outcomes and consumer satisfaction, maintaining ratings over 90%.
Priority Health has formed a strategic partnership with Accolade to enhance healthcare experiences for Michigan employers and their members. This collaboration aims to leverage virtual care and personalized navigation to drive employee engagement and reduce healthcare costs. Through their integrated approach, the two organizations will deliver unique health offerings that prioritize quality and value. This partnership aligns with Priority Health's growth objectives as the state's fastest-growing health plan, while Accolade focuses on empowering individuals to make informed healthcare decisions.
Accolade (Nasdaq: ACCD) has released findings from a report showing how its Personalized Healthcare services enhance employee retention, recruitment, and satisfaction. The research indicates that 93% of Accolade members find their healthcare experience easier, while 92% report improved benefits. The study highlights the importance of mental health and virtual healthcare in the competitive talent market, with 61% of employers looking to expand these services. Key findings show that Accolade members value their health benefits more than non-members, indicating a positive perception of their employer's offerings.
Accolade, Inc. (NASDAQ: ACCD) will participate in the 2022 SVB Leerink Global Healthcare Conference, featuring a fireside chat presentation scheduled for February 18, 2022, at 2:20 p.m. E.T. This event highlights Accolade's commitment to transforming healthcare through personalized, data-driven solutions that enhance member experience.
Accolade serves over 600 employers and millions of members, providing virtual primary care, mental health support, and expert medical opinions, achieving consumer satisfaction ratings above 90%. For more details, visit accolade.com.
Accolade, Inc. (NASDAQ: ACCD) will participate in the 24th Annual Needham Growth Conference, presenting on January 14, 2022, at 12:30 p.m. E.T. The event will be accessible via webcast at ir.accolade.com. Accolade provides personalized healthcare solutions, including virtual primary care and mental health support, serving over 600 employers and millions of members. The company emphasizes a data-driven and value-based approach to healthcare, achieving consumer satisfaction ratings above 90%. For further details, visit accolade.com.
Accolade, Inc. (NASDAQ: ACCD) reported fiscal Q3 2022 revenue of $83.5 million, marking a significant 117% increase from Q3 2021. The company aims for 25% revenue growth in fiscal 2023 while reducing Adjusted EBITDA loss. CEO Rajeev Singh highlighted the transformation into a personalized healthcare provider, growing from 100 customers and 2 million members to over 600 customers and 10 million members in just one year. Accolade successfully launched the Accolade Care and Accolade One services on January 1, 2022, further enhancing their healthcare offerings.
Accolade, Inc. (NASDAQ: ACCD) will release its fiscal Q3 2022 financial results on January 10, 2022, after market close. A conference call will follow at 4:30 p.m. E.T. to discuss these results. The call can be accessed by dialing 1-833-519-1281 for U.S. participants or 1-914-800-3853 for international participants, using conference ID # 6077524. A live audio webcast will also be available on the company's investor relations website. The replay of the call will be accessible for approximately 90 days after the event.
Accolade, Inc. (NASDAQ: ACCD) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference, accessible for registered attendees until December 2, 2021. The company supports over 400 employers and millions of members, focusing on personalized, data-driven healthcare experiences. Accolade combines virtual primary care, mental health support, and expert medical opinions through advanced technology, achieving consumer satisfaction ratings above 90%. For more details, visit accolade.com.
Accolade (Nasdaq: ACCD) has announced an expansion of its executive leadership team, welcoming Carolina Lobo as chief marketing officer and Eve Stacey as chief customer officer. This strategic move aims to enhance the company’s Personalized Healthcare offerings, fostering better healthcare experiences for over 400 enterprise customers and nine million members. Lobo will lead brand strategy and engagement, while Stacey will focus on customer success operations. Both leaders bring extensive experience from notable companies, positioning Accolade to strengthen its mission in delivering exceptional healthcare solutions.
FAQ
What is the current stock price of Accolade (ACCD)?
What is the market cap of Accolade (ACCD)?
What does Accolade, Inc. do?
How has Accolade performed financially recently?
What is the Trusted Partner Ecosystem?
Who are Accolade's key partners?
What recognition has Accolade received?
What is Accolade's mission?
How does Accolade contribute to healthcare cost reduction?
How does Accolade engage with its members?
What is Accolade's customer satisfaction rating?
Where can I find more information about Accolade?
